Israel - English - Ministry of Health

bayer israel ltd, israel - vericiguat - film coated tablets - vericiguat 10 mg - vericiguat - verquvo is indicated to reduce the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for heart failure or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%.

Israel - English - Ministry of Health

bayer israel ltd, israel - vericiguat - film coated tablets - vericiguat 2.5 mg - vericiguat - verquvo is indicated to reduce the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for heart failure or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%.

Israel - English - Ministry of Health

bayer israel ltd, israel - vericiguat - film coated tablets - vericiguat 5 mg - vericiguat - verquvo is indicated to reduce the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for heart failure or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - vericiguat (unii: lv66adm269) (vericiguat - unii:lv66adm269) - verquvo® is indicated to reduce the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for heart failure or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45% [see clinical studies (14)] . verquvo is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sgc) stimulators [see drug interactions (7.1)] . verquvo is contraindicated in pregnancy [see warnings and precautions (5.1) and use in specific populations (8.1)]. pregnancy surveillance program there is a pregnancy surveillance program that monitors pregnancy outcomes in women exposed to verquvo during pregnancy. health care providers should report any prenatal exposure to verquvo by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com. risk summary based on data from animal reproduction studies, verquvo may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see co

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vericiguat, quantity: 5 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; microcrystalline cellulose; iron oxide red; sodium lauryl sulfate; purified talc; croscarmellose sodium; titanium dioxide - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vericiguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; microcrystalline cellulose; purified talc; hypromellose; sodium lauryl sulfate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vericiguat, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; purified talc; titanium dioxide; croscarmellose sodium; sodium lauryl sulfate; iron oxide yellow; magnesium stearate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

European Union - English - EMA (European Medicines Agency)

bayer ag - vericiguat - heart failure - cardiac therapy - treatment of symptomatic chronic heart failure

Canada - English - Health Canada

bayer inc - vericiguat - tablet - 2.5mg - vericiguat 2.5mg

Canada - English - Health Canada

bayer inc - vericiguat - tablet - 5mg - vericiguat 5mg